Zymeworks agreed to acquire Theravance Biopharma for about $929 million, paying $17 per share, to add commercial and late-stage COPD exposure through Theravance’s Yupelri profit stream. The transaction also brings payouts tied to Trelegy milestones and is structured to limit Zymeworks’ net capital at risk.